Datum | Källa | Rubrik | Typ | Alternativ | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-05-08 | Penser Access by Carnegie | Penser Access by Carnegie: Ascelia Pharma: Medvind i seglen | Pressreleaser | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-05-07 | Ascelia Pharma | Välkommen till Ascelia Pharma uppdatering till investerare: Att föra Orviglance till patienterna | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-05-07 | Ascelia Pharma | Welcome to Ascelia Pharma Investor Update: Bringing Orviglance to Patients | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-05-06 | Ascelia Pharma | Kommuniké från årsstämma den 6 maj 2024 i Ascelia Pharma AB | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-05-06 | Ascelia Pharma | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 6 May 2024 | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-05-02 | Ascelia Pharma | Ascelia Pharma uppnår framgångsrikt det primära effektmåttet med starka headline-resultat i fas 3-studien med Orviglance | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-05-02 | Ascelia Pharma | Ascelia Pharma Successfully Meets Primary Endpoint with Strong Headline Results in Orviglance Phase 3 Study | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-04-18 | Ascelia Pharma | Ascelia Pharma Draws Down SEK 15 Million Second Tranche Under Existing Loan Facility | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-04-18 | Ascelia Pharma | Ascelia Pharma utnyttjar den andra tranchen om 15 MSEK under befintlig lånefacilitet | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-04-10 | Ascelia Pharma | Ascelia Pharma Reports SPARKLE Image Reading Completion and Expects Headline Results First Half of May 2024 | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-04-10 | Ascelia Pharma | Ascelia Pharma rapporterar att SPARKLE-bildläsningsfasen är avslutad och förväntar sig headline-resultat i första halvan av maj 2024 | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-04-08 | Ascelia Pharma | Årsredovisning 2023: Solida framsteg med slutförd patientrekrytering till Orviglance fas 3 och förväntat headline-resultat i maj 2024 | Rapporter | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-04-08 | Ascelia Pharma | Annual Report 2023: Solid Progress with Orviglance Phase 3 Patient Recruitment Completed and Headline Results Expected by May 2024 | Rapporter | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-03-27 | Ascelia Pharma | Notice of Annual General Meeting in Ascelia Pharma AB | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
Pressreleaser |
Notice of Annual General Meeting in Ascelia Pharma ABThe English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. The shareholders in Ascelia Pharma AB, Reg. No. 556571-8797, are hereby invited to the annual general meeting (Sw. årsstämma) to be held at the premises of Setterwalls Advokatbyrå at Stortorget 23 in Malmö on Monday 6 May 2024 at 2 p.m. CEST. Right to participate and notice of participation
Trustee-registered shares Proxies etc. Proposed agenda
Proposed resolutions Item 1: Election of chairman of the meeting Item 8 b: Resolution regarding allocation of the company’s profits in accordance with the adopted balance sheet Item 9: Determination of the number of members of the board of directors, auditors and deputy auditors Furthermore, the Nomination Committee proposes, in accordance with the recommendation from the Audit Committee, that one registered accounting firm is appointed as auditor. Item 10: Determination of remuneration for the members of the board of directors and for the auditors All proposed remunerations are unchanged from previous year. Furthermore, the Nomination Committee proposes, in accordance with the recommendation from the Audit Committee, that remuneration for the auditor shall be paid in accordance with customary norms and approved invoice. Item 11: Election of members of the board of directors, chairman of the board of directors and auditor Information on the board members proposed for re-election can be found at the company’s website ( www.ascelia.com ) and in the annual report. Furthermore, the Nomination Committee proposes, in accordance with the recommendation from the Audit Committee, that Öhrlings PricewaterhouseCoopers AB is re-elected as accounting firm. Öhrlings PricewaterhouseCoopers AB has informed that the authorized public accountant Mikael Nilsson will be the auditor in charge. Item 12: Resolution on remuneration of the Nomination Committee for work ahead of the annual general meeting in 2025 Item 13: Resolution on approval of remuneration report Item 14: Resolution on authorization for the board of directors regarding issues The CEO shall be authorized to make minor formal adjustments of the resolution which may be required for registration with the Swedish Companies Registration Office (Sw. Bolagsverket). Item 15: Resolution on implementation of a long-term incentive program by way of (a) implementation of a performance-based share saving program; (b) authorization on directed issues of series C shares; (c) authorization for repurchase of series C shares; and (d) resolution on transfer of own ordinary shares a. Implementation of a performance-based share saving program At previous annual general meetings, it has been resolved to implement corresponding incentive programs for employees in the company, and currently LTI 2021, LTI 2022 and LTI 2023 are outstanding. Terms and conditions for LTI 2024
4.The board of directors shall, within the limits stated above, resolve on the maximum number of Saving Shares that each individual participant may acquire/allocate. b. Authorization on directed issues of series C shares c. Authorization on repurchase of series C shares Since LTI 2024 is not expected to initially give rise to any costs for social security contributions for the company (and since a resolution on transfer is valid only until the next annual general meeting), the board of directors has decided not to propose that the annual general meeting 2024 resolves on an authorization for the board of directors to transfer the company’s own ordinary shares on a regulated market for hedging of cash flow for social security payments in relation to LTI 2024. However, before any transfers of shares to participants in LTI 2024 are made, the board of directors intends to propose to a later general meeting to resolve on an authorization for the board of directors to transfer own ordinary shares on a regulated marked in order to hedge such payments. Costs, impact on key ratios, existing incentive programs and dilution The anticipated annual costs of approximately SEK 3.57 million, including social security contributions, correspond to approximately 8.63 per cent of the company’s total employee costs for the financial year 2023. Based on the calculation of costs as described above, the key figure earnings per share for the financial year 2023 had been changed from SEK -3.24 to SEK -3.35. It should be noted that the calculations are based on the assumptions stated above and are only intended to provide an illustration of the outcome. As per the date of the notice, the number of shares in the company amounts to 34,871,177 shares, of which 33,757,746 are ordinary shares and 1,113,431 are series C shares which were issued in connection with outstanding share saving programs resolved upon at previous annual general meetings, and which will be converted into ordinary shares prior to delivery to the participants. The Company currently has four outstanding incentive programs, of which three are performance-based share saving programs and one is an employee option program. For a description of the outstanding incentive programs, see note 7 in the annual report for 2023. In the outstanding share saving programs, the participants may receive matching shares and, subject to conditions related to an increase in the share price, performance shares. In light of the company’s implemented downsizing of the organization in 2023 and the company’s share price development, the board of directors considers it uncertain that any performance shares will be delivered to participants in the outstanding share saving programs since the performance targets for the company’s share price in the programs far exceed the current share price, and that only matching shares may be delivered to the participants who are still employed by the company. Nevertheless, in the calculation of total dilution from existing incentive programs below, delivery of performance shares has been included. In addition, the dilution below includes conversion of series C shares to ordinary shares that the company may convert and transfer for hedging of cash flow for any social security contributions that may arise as a result of the outstanding programs. The maximum number of ordinary shares that can be issued in relation to existing share saving programs thus amounts to a total of 1,205,398, and upon full exercise of the employee options that are held by the participants in the employee option program, a maximum of 1,720,000 new ordinary shares may be issued. The existing incentive programs can hence lead to that in the aggregate 2,925,398 new ordinary shares can be issued. The aggregate maximum number of ordinary shares that can be issued in relation to all outstanding incentive programs as well as the proposed LTI 2024 amounts to 4,806,832, which corresponds to an aggregate dilution of approximately 12.46 per cent of the company’s ordinary shares after full dilution, calculated on the number of ordinary shares that may be issued in relation to all outstanding incentive programs as well as the suggested LTI 2024. The above calculations regarding dilution are subject to re-calculation in accordance with the customary recalculation terms included in the complete applicable terms. Preparation of the proposal and other information The board of directors’ proposal on implementation of a long-term incentive program in accordance with Sections a to d above constitutes an overall proposal which shall be resolved upon as one resolution. The chairman of the board of directors, or anyone appointed by him, shall be authorized to make minor formal adjustments of the resolution which may be required for registration with the Swedish Companies Registration Office (Sw. Bolagsverket) or Euroclear Sweden AB. Item 16: Resolution on authorization for the board of directors regarding transfer of own ordinary shares Particular majority requirements Shareholders’ right to information Meeting documents Number of shares and votes in the company Processing of personal data |
||||||||||||||||||
2024-03-27 | Ascelia Pharma | Kallelse till årsstämma i Ascelia Pharma AB | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-02-21 | Penser Access by Carnegie | Penser Access by Carnegie: Interview with Ascelia Pharma - Carnegie Investment Bank - Feb 21th 2024 | Pressreleaser | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-02-12 | Penser Access by Carnegie | Penser Access by Carnegie: Ascelia Pharma - Finansiering på plats, avgörande data i maj | Pressreleaser | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-02-12 | Redeye | Redeye: Ascelia Pharma Q4 2023 - On track with easing financial pressure | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-02-09 | Ascelia Pharma | Q4 and Full Year Report 2023: Strengthened Financial Position Ahead of SPARKLE Phase 3 Study Headline Results in May | Rapporter | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-02-09 | Ascelia Pharma | Q4 och bokslutskommuniké 2023: Stärkt finansiell position inför headline-resultat i maj för den kliniska fas-3 studien SPARKLE | Rapporter | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-02-04 | Ascelia Pharma | Ascelia Pharma säkrar finansiering om upp till 35 MSEK | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-02-04 | Ascelia Pharma | Ascelia Pharma Secures Financing of up to SEK 35 Million | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-01-24 | Ascelia Pharma | Orviglance Review Article Published in Investigative Radiology | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-01-24 | Ascelia Pharma | Översiktsartikel om Orviglance publicerad i Investigative Radiology | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-01-24 | Ascelia Pharma | Nomination Committee Appointed for AGM 2024 in Ascelia Pharma AB | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2024-01-24 | Ascelia Pharma | Valberedning utsedd i Ascelia Pharma AB inför årsstämman 2024 | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-12-07 | Ascelia Pharma | Ascelia Pharma Announces Start of Image Reading Phase and Re-confirms Phase 3 SPARKLE Results by May 2024 | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-12-07 | Ascelia Pharma | Ascelia Pharma meddelar start av bildläsningsfasen och bekräftar resultat från fas 3 SPARKLE senast i maj 2024 | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-12-06 | Finansinspektionen | Finansinspektionen: Flaggningsmeddelande i Ascelia Pharma AB | Pressreleaser | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-11-30 | Ascelia Pharma | Change in Number of Shares and Votes in Ascelia Pharma AB | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-11-30 | Ascelia Pharma | Ändring av antalet aktier och röster i Ascelia Pharma AB | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-11-13 | Ascelia Pharma | Kommuniké från extra bolagsstämma den 13 november 2023 i Ascelia Pharma AB | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-11-13 | Ascelia Pharma | Bulletin from the Extraordinary General Meeting in Ascelia Pharma AB on 13 November 2023 | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-11-09 | Ascelia Pharma | Ascelia Pharma beslutar om omvandling av C-aktier till stamaktier för leverans till deltagare i incitaments-program | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-11-09 | Ascelia Pharma | Ascelia Pharma resolves on conversion of series C shares into ordinary shares for delivery to participants in incentive program | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-11-09 | Penser Access | Penser Access: Blickarna mot maj - Ascelia Pharma | Pressreleaser | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-11-09 | Redeye | Redeye: Ascelia Q3 update - On track for a SPARKLE result in May 2024 | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-11-08 | Ascelia Pharma | KVARTALSRAPPORT Q3 2022: Den ny utläsning av bilderna från fas 3-studien SPARKLE fortskrider enligt planen | Rapporter | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-11-08 | Ascelia Pharma | QUARTERLY REPORT Q3 2023: Re-evaluation of SPARKLE Phase 3 Study Images Progresses According to Plan | Rapporter | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-10-19 | Ascelia Pharma | KALLELSE TILL EXTRA BOLAGSSTÄMMA I ASCELIA PHARMA AB | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-10-19 | Ascelia Pharma | NOTICE OF EXTRAORDINARY GENERAL MEETING IN ASCELIA PHARMA AB | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-10-04 | Ascelia Pharma | Ascelia Pharma Gets Acceptance for Publication of Orviglance Review Article in Investigative Radiology | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-10-04 | Ascelia Pharma | Ascelia Pharma får översiktsartikel om Orviglance accepterad för publicering i Investigative Radiology | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-09-18 | Redeye | Redeye: Ascelia Pharma - All attention on the top priority | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-09-13 | Ascelia Pharma | Ascelia Pharma to Reach Headline Results from SPARKLE Re-Evaluation by May 2024 with Current Funding | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-09-13 | Ascelia Pharma | Ascelia Pharma når headline-resultat från SPARKLE-utläsningen i maj 2024 med nuvarande finansiering | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-08-31 | Ascelia Pharma | Ascelia Pharma gör omfattande neddragning av organisationen för att nå headline-resultat med SPARKLE | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-08-31 | Ascelia Pharma | Ascelia Pharma significantly reduces organization to reach SPARKLE headline results | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-08-21 | Penser Access | Penser Access: I väntan på nästa milstolpe - Ascelia Pharma | Pressreleaser | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-08-18 | Ascelia Pharma | Halvårsrapport 2023: Ny utläsning krävs efter intraläsarinkonsistens rörande poängsättning av bilder av läsare från fas 3-studien SPARKLE | Rapporter | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-08-18 | Ascelia Pharma | Half-Year report 2023: Re-evaluation required after intra-reader inconsistency in scoring of images from phase 3 study SPARKLE | Rapporter | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-08-09 | Ascelia Pharma | Ascelia Pharma ger förtydliganden kring intraläsarvariabilitet vid utläsningen av bilder i SPARKLE-studien | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-08-09 | Ascelia Pharma | Ascelia Pharma provides clarifications around the intra-reader variability in read-out of images in the SPARKLE study | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-08-09 | Penser Access | Penser Access: Oväntat utfall - Ascelia Pharma | Pressreleaser | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-08-09 | Redeye | Redeye: Ascelia Pharma - SPARKLE is blurred | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-08-07 | Ascelia Pharma | Re-Evaluation Required After Intra-Reader Inconsistency in Scoring of Images from Phase 3 Study SPARKLE | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-08-07 | Ascelia Pharma | Ny utläsning krävs efter intraläsarinkonsistens rörande poängsättning av bilder av läsare från fas 3-studien SPARKLE | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-06-20 | Penser Access | Penser Access: Sanningens ögonblick - Ascelia Pharma | Pressreleaser | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-06-16 | Ascelia Pharma | Ascelia Pharma presented Orviglance Hepatic Impairment Data and hosted a Q&A with liver imaging experts at the 2023 ESGAR Annual Meeting | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-06-16 | Ascelia Pharma | Vid ESGARs årsmöte 2023 presenterade Ascelia Pharma Orviglance-data från studien med nedsatt leverfunktion samt var värd för en Q&A med experter inom leveravbildning | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-05-15 | Redeye | Redeye: Ascelia Pharma - SPARKLE is about to sparkle | Pressreleaser | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-05-12 | Penser Access | Penser Access: Nyckelhändelse stundar - Ascelia Pharma | Pressreleaser | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-05-11 | Ascelia Pharma | KVARTALSRAPPORT Q1 2023: Fas 3 studien för Orviglance, SPARKLE, sista patientens sista besök (Last Patient Last Visit, LPLV) har avslutats | Rapporter | Ladda ner | Visa Stäng | ||||||||||||||
|
||||||||||||||||||
2023-05-11 | Ascelia Pharma | QUARTERLY REPORT Q1 2023: Orviglance phase 3 study, SPARKLE, Last Patient Last Visit (LPLV) has been completed | Rapporter | Ladda ner | Visa Stäng | ||||||||||||||
|